Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. 2013

Andrew Anglemyer, and George W Rutherford, and Tara Horvath, and Rachel C Baggaley, and Matthias Egger, and Nandi Siegfried
Global Health Sciences, University of California, San Francisco, San Francisco, California, USA.

BACKGROUND Antiretroviral drugs have been shown to reduce risk of mother-to-child transmission of human immunodeficiency virus (HIV) and are also widely used for post-exposure prophylaxis for parenteral and sexual exposures. Sexual transmission may be lower in couples in which one partner is infected with HIV and the other is not and the infected partner is on antiretroviral therapy (ART). OBJECTIVE To determine if ART use in an HIV-infected member of an HIV-discordant couple is associated with lower risk of HIV transmission to the uninfected partner compared to untreated discordant couples. METHODS We used standard Cochrane methods to search electronic databases and conference proceedings with relevant search terms without limits to language. METHODS Randomised controlled trials (RCT), cohort studies and case-control studies of HIV-discordant couples in which the HIV-infected member of the couple was being treated or not treated with ART DATA COLLECTION AND ANALYSIS: Abstracts of all trials identified by electronic or bibliographic scanning were examined independently by two authors. We initially identified 3,833 references and examined 87 in detail for study eligibility. Data were abstracted independently using a standardised abstraction form. RESULTS One RCT and nine observational studies were included in the review. These ten studies identified 2,112 episodes of HIV transmission, 1,016 among treated couples and 1,096 among untreated couples. The rate ratio for the single randomised controlled trial was 0.04 [95% CI 0.00, 0.27]. All index partners in this study had CD4 cell counts at baseline of 350-550 cells/µL. Similarly, the summary rate ratio for the nine observational studies was 0.58 [95% CI 0.35, 0.96], with substantial heterogeneity (I(2)=64%). After excluding two studies with inadequate person-time data, we estimated a summary rate ratio of 0.36 [95% CI 0.17, 0.75] with substantial heterogeneity (I(2)=62%). We also performed subgroup analyses among the observational studies to see if the effect of ART on prevention of HIV differed by the index partner's CD4 cell count. Among couples in which the infected partner had ≥350 CD4 cells/µL, we estimated a rate ratio of 0.12 [95% CI 0.01, 1.99]. In this subgroup, there were 247 transmissions in untreated couples and 30 in treated couples. CONCLUSIONS ART is a potent intervention for prevention of HIV in discordant couples in which the index partner has ≤550 CD4 cells/µL. A recent multicentre RCT confirms the suspected benefit seen in earlier observational studies and reported in more recent ones. Questions remain about durability of protection, the balance of benefits and adverse events associated with earlier therapy, long-term adherence and transmission of ART-resistant strains to partners. Resource limitations and implementation challenges must also be addressed.Counselling, support, and follow up, as well as mutual disclosure, may have a role in supporting adherence, so programmes should be designed with these components. In addition to ART provision, the operational aspects of delivering such programmes must be considered.

UI MeSH Term Description Entries
D008297 Male Males
D005260 Female Females
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012747 Sexual Partners Married or single individuals who share sexual relations. Multiple Partners Sexual,Multiple Sex Partners,Multiple Sexual Partners,Sex Partners,Partner, Sex,Partner, Sexual,Sex Partner,Sex Partner, Multiple,Sex Partners, Multiple,Sexual Partner,Sexual Partner, Multiple
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D059147 HIV Serosorting The practice of making choices about SEXUAL PARTNERS based on their HIV status. Serosorting, HIV
D018023 HIV Seronegativity Immune status consisting of non-production of HIV antibodies, as determined by various serological tests. HTLV-III Seronegativity,HIV Seronegativities,HTLV III Seronegativity,HTLV-III Seronegativities,Seronegativities, HIV,Seronegativities, HTLV-III,Seronegativity, HIV,Seronegativity, HTLV-III
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts

Related Publications

Andrew Anglemyer, and George W Rutherford, and Tara Horvath, and Rachel C Baggaley, and Matthias Egger, and Nandi Siegfried
March 2012, American family physician,
Andrew Anglemyer, and George W Rutherford, and Tara Horvath, and Rachel C Baggaley, and Matthias Egger, and Nandi Siegfried
January 2013, PloS one,
Andrew Anglemyer, and George W Rutherford, and Tara Horvath, and Rachel C Baggaley, and Matthias Egger, and Nandi Siegfried
July 2018, AIDS (London, England),
Andrew Anglemyer, and George W Rutherford, and Tara Horvath, and Rachel C Baggaley, and Matthias Egger, and Nandi Siegfried
February 2011, AIDS (London, England),
Andrew Anglemyer, and George W Rutherford, and Tara Horvath, and Rachel C Baggaley, and Matthias Egger, and Nandi Siegfried
June 2021, Sexually transmitted diseases,
Andrew Anglemyer, and George W Rutherford, and Tara Horvath, and Rachel C Baggaley, and Matthias Egger, and Nandi Siegfried
January 2013, AIDS care,
Andrew Anglemyer, and George W Rutherford, and Tara Horvath, and Rachel C Baggaley, and Matthias Egger, and Nandi Siegfried
July 2008, Lancet (London, England),
Andrew Anglemyer, and George W Rutherford, and Tara Horvath, and Rachel C Baggaley, and Matthias Egger, and Nandi Siegfried
October 2000, The AIDS reader,
Andrew Anglemyer, and George W Rutherford, and Tara Horvath, and Rachel C Baggaley, and Matthias Egger, and Nandi Siegfried
November 2011, Journal of acquired immune deficiency syndromes (1999),
Andrew Anglemyer, and George W Rutherford, and Tara Horvath, and Rachel C Baggaley, and Matthias Egger, and Nandi Siegfried
March 2018, The lancet. HIV,
Copied contents to your clipboard!